NCT06402630Phase 2Completed
A Phase 2 Placebo Controlled, Clinical Trial Designed to Assess the Efficacy, Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderate Alopecia Areata (AA)
A Phase 2 Double-blind, Multicentre, Placebo Controlled, Parallel Group Design to Assess the Efficacy, Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderate Alopecia Areata (AA)
In the register
The register attaches this trial to STS01 (Soterios Pharma), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2
- Sponsor
- Soterios Ltd
- Participants (registry)
- 158
- Start
- March 2022
- Primary completion
- April 2024
- Study completion
- April 2024
- Last registry update
- May 2024
- Countries
- United Kingdom
Conditions studied: Alopecia Areata
Interventions: STS01, Placebo
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.